OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...
Core Molding Technologies Publishes Its 2nd Annual Sustainability Report COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada, and Mexico today announced the release of its second annual Sustainability Report, which focuses on its Environmental, Social, and Governance ...
Core Molding Technologies Announces Timing of First Quarter Fiscal Year 2024 Results COLUMBUS, Ohio, April 18, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, utilities, transportation and powersports industries across North America, today announces that it will release its first quarter fiscal year 2024 results on Tuesday, May 7, 2024, before the market opens. In conjunction with the release, the Comp...
Core Molding Technologies Presented with a 2024 BRP Gold Supplier Award Featuring BRP Sea-Doo Boat and Personal Watercraft Models COLUMBUS, Ohio, April 16, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”) announced it was presented with BRP’s Gold Supplier Award based on excellence in quality, manufacturing, and logistics related to its Sea-Doo boat and personal watercraft models. BRP awards the Gold Supplier Award to suppliers that have provided excellent customer service and technical support. The award is based o...
A director at Protagonist Therapeutics Inc sold 25,000 shares at 28.310USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Core Molding Technologies Promotes Eric L. Palomaki to Chief Operating Officer COLUMBUS, Ohio, March 25, 2024 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding,” “Core” or the “Company”), announced today that Eric L. Palomaki has been promoted to Chief Operating Officer (“COO”). In his new role as COO, Mr. Palomaki will assume responsibility for the procurement function within Core Molding along with his current responsibilities of leading the company's day-to-day operations, driving operational excellence, program management, growing the research ...
A director at Opko Health Inc bought 500,000 shares at 0.874USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Homology Medicines Declares Distribution to Common Stockholders BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held by such stockholder as of such record date. The payment date for such distribution is expected to be March 27, 2024 (three business days after the expected closing of the merger on March 22, 2024...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.